Benjamin Meder
Has grant
W3 Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
STAR family function and interaction with RBM20 for intervening alternative splicing (A07)
Open Date: 2022-01-01
Close Date:
Grant: Close
Cardiac Splicing as a Therapeutic Target (CASTT)
Open Date: 2021-01-01
Close Date:
Grant: Close
Cardiac myosin light chain 1 dependent regulatory mechanisms in dilated cardiomyopathy
Open Date: 2019-01-01
Close Date:
Grant: Close
Hereditary sick sinus syndrome – phenotypic spectrum, genetic basis, cellular dysfunction and implications for therapy
Open Date: 2018-01-01
Close Date: 2022-12-31
Articles (6)
Hypertrophic cardiomyopathy (HCM) represents the most common inherited cardiac disease and a leading cause of heart failure, arrhythmias, and sudden cardiac death in young individuals. For decades, management of HCM has relied on symptom control with β-blockers, calcium channel blockers, disopyramide, or invasive septal reduction in advanced cases. The identification of pathogenic sarcomere variants and the recognition of hypercontractility as a central disease mechanism have paved the way for cardiac myosin inhibitors (CMIs), the first truly disease-specific pharmacological therapy for HCM. Indeed, CMIs represent a revolutionary therapeutic paradigm that redefines the standard of care by translating molecular discovery into clinical application. This review provides a guide to the mechanistic basis of sarcomere modulation, summarizes the clinical evidence for mavacamten and aficamten, and critically evaluates the evolving roles of both medications in obstructive and non-obstructive HCM.
Year:
2026
Background The clinical and economic burden of obstructive hypertrophic cardiomyopathy (HCM) in Germany for symptomatic versus asymptomatic patients has not been comprehensively assessed. Methods This retrospective observational study analyzed nationally representative WIG2 Benchmark Database data, identifying adults diagnosed with obstructive HCM from 2012 to 2018. Study index was the first date when a participant met eligibility criteria. An algorithm based on coded symptoms and pharmacological treatments was used to divide patients into symptomatic and asymptomatic subgroups. Annual prevalence, patient characteristics, outcomes, resource utilization, and costs were assessed during follow-up. Results Overall, 1141 patients were included (649 symptomatic patients and 492 asymptomatic patients during the 1-year pre-index period [baseline]). In total, 1042 patients had symptomatic disease at some point during follow-up. Annual obstructive HCM prevalence increased between 2011 and 2019 and was higher for symptomatic than asymptomatic patients. Compared with asymptomatic patients, symptomatic patients: were older (mean age: 62.8 vs. 55.5 years), were less likely to be male (59% vs. 67%), and had higher Charlson Comorbidity Index (mean: 2.82 vs. 1.69) at baseline; had higher rates of all-cause mortality (0.05 vs. 0.02 per 100 patient-years) and cardiovascular events (mean follow-up: 4.7 years); had more outpatient visits (13.3 vs. 10.8 per patient-year [PPY]), inpatient visits (0.7 vs. 0.5 PPY), and longer mean length of stay (8.7 vs. 7.4 days); and had higher mean costs PPY for outpatient, inpatient, and pharmacy services (total: €5975 vs. €4399). Conclusions Patients with symptomatic obstructive HCM experienced greater clinical and economic burden than asymptomatic patients in Germany. Graphical Abstract
Year:
2025
Background Genetic diagnosis has become increasingly important to guide clinical decision making for patients with dilated cardiomyopathy (DCM). Disease-causing (P/LP) missense variants in the gene RBM20 cause a highly penetrant arrhythmogenic dilated cardiomyopathy (DCM), but the role of truncating RBM20 variants ( RBM20tvs ) is unclear. Objective Assess the contribution of RBM20tvs to DCM. Methods We assembled an international cohort of DCM patients with RBM20 variants and used data from the genome-first UK Biobank (UKB) to assess the etiologic fraction, natural history and penetrance of RBM20tvs . Results The etiologic fraction of RBM20tvs in arrhythmogenic DCM was modest (0.53[0.32,0.67], p=7.5×10 -5 ). RBM20tv DCM patients presented to referral centers later in life than RBM20 P/LP DCM patients (53±10 vs. 34±18 years, p=4×10 -3 ), and were less likely to have a family history of sudden cardiac arrest (20% vs. 65%, p= 0.046) or cardiomyopathy (20% vs. 78% p=5.4×10 -3 ). There was no significant difference in age- and sex-adjusted incident major heart failure or arrhythmia events between RBM20tv and RBM20 P/LP DCM patients, though sex-adjusted lifetime hazard was reduced in RBM20tv DCM (HR 0.15[0.03,0.66],p=0.009). In UKB, lifetime incidence of cardiomyopathy, heart failure, or major ventricular arrhythmia diagnosis was lower in participants with RBM20tvs than in those with TTNtvs (HR 0.55 [0.36,0.84], p=5.9×10 -3 ). Conclusions RBM20tvs contribute to arrhythmogenic DCM phenotypes, but confer milder disease severity alone than RBM20 P/LP variants, and reduced lifetime disease penetrance compared to TTNtvs . Their potential for additive interactions with other damaging variants should be considered in DCM patients and families.
Year:
2025
Dysregulation of alternative splicing – mediated by factors such as RBM20 or SLM2 – can affect proper gene isoform control disrupts gene isoform homeostasis and underpins severe cardiomyopathy in both animal models and patients. Although innovative therapies target various sarcomeric components, the impact of isoform switching in cardiac disease remains poorly understood. Here, we applied nanopore long-read sequencing to map the full-length transcriptome of left ventricular tissue from thirteen nonfailing controls, ten patients with dilated cardiomyopathy (DCM), and ten with ischemic cardiomyopathy (ICM). Our analysis identified 78,520 transcripts, 31% of which represent novel isoforms of known genes. Notably, the transcriptomes of DCM and ICM were largely indistinguishable, indicating that end-stage heart failure is characterized by a convergent isoform landscape, irrespective of disease etiology. Among 11 prototypical sarcomere genes, 10 displayed highly significant isoform shifts (p= 5.23×10 −45 – 2.89×10 −200 ). Focusing on tropomyosin, we observed that while the predominant cardiac gene TPM1 showed moderate up-regulation of its transcript isoforms, transcripts derived from TPM3 —typically expressed at lower levels in the healthy heart—were markedly increased in heart failure.
Year:
2025
Was ist neu? Die Leitlinien bieten aktualisierte Klassifikationen für die dilatierte und nicht dilatierte linksventrikuläre (LV) Kardiomyopathie, wobei besonderer Wert auf die Bedeutung der kardialen Magnetresonanztomografie (CMR: Cardiovascular Magnetic Resonance) zur Beurteilung des Myokards gelegt wird. Es wird ein besonderer Fokus auf den klinischen Verlauf gelegt, von der Erstvorstellung über die Diagnose, bis hin zum Management, wobei die Notwendigkeit eines systematischen, multiparametrischen Ansatzes zur Identifizierung der zugrundeliegenden Ursache der Kardiomyopathie betont wird. Neue Empfehlungen heben die Bedeutung des klinischen und genetischen Kaskaden-Screenings für Familienmitglieder von Personen mit Kardiomyopathie hervor. Die Leitlinien betonen die Notwendigkeit einer kontinuierlichen Versorgung – beginnend in der Kindheit bis ins Erwachsenenalter, insbesondere während wichtiger Übergangsphasen – und behandeln die verschiedenen klinischen Stadien der Kardiomyopathien (z.B. subklinisch, symptomatisch erkrankt, Endstadium). Die Leitlinien betonen die Bedeutung eines multidisziplinären Ansatzes, der die Einbeziehung verschiedener Fachrichtungen und die Einbindung der Familie in den Behandlungsprozess vorsieht. Es werden neue Richtlinien zur Risikobewertung für SCD bei verschiedenen Kardiomyopathie-Phänotypen gegeben, einschließlich Empfehlungen für pädiatrische Populationen, mit einem Schwerpunkt bezüglich genetischer Faktoren bei der Risikobewertung. Aktualisierte Empfehlungen zum Management von LVOTO, einer häufigen Manifestation der HCM. Die Taskforce empfiehlt, den Begriff „Hypertrabekularisierung“ statt LVNC zu verwenden und das Takotsubo-Syndrom nicht als Kardiomyopathie zu klassifizieren, da es sich dabei meist um vorübergehende Phänomene handelt.
Year:
2025
BACKGROUND Technological advances allow for recording and sharing health-related data in a patient-centric way using smartphones and wearables. Secure sharing of such patient-generated data with physicians would enable close management of individual health trajectories, monitoring of risk factors, and asynchronous feedback. However, most remote patient monitoring (RPM) systems currently available are not fully integrated into hospital IT systems or lack a patient-centric design. OBJECTIVE The objective of this study was to conceptualize and implement a user-friendly, reusable, interoperable, and secure RPM system incorporating asynchronous feedback mechanisms using a broadly available consumer wearable (Apple Watch). In addition, this study sought to evaluate factors influencing patient acceptance of such systems. METHODS The RPM system requirements were established through focus group sessions. Subsequently, a system concept was designed and implemented using an iterative approach ensuring technical feasibility from the beginning. To assess clinical feasibility, the system was used as part of the activeDCM prospective randomized interventional study focusing on dilated cardiomyopathy. Each patient used the system for at least 12 months. The System Usability Scale was used to measure usability from a subjective patient perspective. In addition, an evaluation was conducted on the objective wearable interaction frequency as well as the completeness of transmitted data classified into sensor-based health data (SHD) and patient-reported outcome measures (PROMs). Descriptive statistics using box plots and bootstrapped multiple linear regression with 95% CIs were used for evaluation analyzing the influence of age, sex, device experience, and intervention group membership. RESULTS The RPM system comprised 4 interoperable components: patient devices, a data server, a data viewer, and a notification service. The system was evaluated with 95 consecutive patients with dilated cardiomyopathy (28/95, 29% female; mean age 50, SD 12 y) who completed the activeDCM study protocol. The system’s app achieved a mean System Usability Scale score of 78 (SD 17), which was most influenced by device experience. In total, 87% (83/95) of the patients could integrate the use of the app well or very well into their daily routine, and 71% (67/95) saw a benefit of the RPM system for management of their health condition. On average, patients interacted with the wearable on 61% (SD 26%) of days enrolled in the study. SHD were available on average for 78% (SD 23%) of days, and PROM data were available on 64% (SD 27%) of weeks enrolled in the study. Wearable interaction frequency, SHD, and PROM completeness were most influenced by intervention group membership. CONCLUSIONS Our results mark a first step toward integrating RPM systems based on a consumer wearable device for primary patient input into standardized clinical workflows. They can serve as a blueprint for creating a user-friendly, reusable, interoperable, and secure RPM system that can be integrated into patients’ daily routines.
Year:
2024
Collaborators (27)
Dirk Grimm
Heidelberg University
Sharlene Day
Associate Professor
University of Pennsylvania
Anjali T. Owens
Assistant Professor, Clinician-Educator
University of Pennsylvania Perelman School of Medicine
Eric Smith
University of Michigan
Bruna Filipa Gomes Botelho Quintas
Fachärztin
University Hospital Heidelberg
Tarcyane Garcia
WIG2 Institute for Health Economics and Health System Research
Daniel Judge
Professor
Medical University of South Carolina
Julia Cadrin-Tourigny
Clinical Assistant Professor
Université de Montréal
Adam Helms
Assistant Professor
University of Michigan
Birgit Friedmann-Bette
University Hospital Heidelberg
Vasanth Vedantham
Professor
University of California, San Francisco
Andrew D Krahn
Professor
The University of British Columbia
Diane Fatkin
Victor Chang Cardiac Research Institute
Gianfranco Sinagra
University of Trieste
Cynthia James
Associate Professor
Johns Hopkins University
Nosheen Reza
University of Pennsylvania
Euan A. Ashley
Professor
Stanford University School of Medicine
Christoph Reich
University Hospital Heidelberg
Ardan M. Saguner
-
Johannes Backs
Professor
Heidelberg University
Kristen Medo
Research Services Professional
University of Colorado Anschutz Medical Campus
Luisa Mestroni
Professor of Medicine
University of Colorado Anschutz Medical Campus
Andreas S. Barth
Assistant Professor
Johns Hopkins University
Chad Mao
Children's Healthcare of Atlanta
Marc Freichel
Professor at Heidelberg University
Heidelberg University
Perry Elliott
University College London
Manuel Taft
Chemiker / Biochemiker
Hannover Medical School
Make your next move.
Prepare your application
Review drafts before you send them.